Tesamorelin
- TRADE NAME: Egrifta (Theratechnologies)
- INDICATIONS: Reduction of excess abdominal fat in HIV-infected patients with lipodystrophy
- CLASS: Growth hormone-releasing hormone analog
- HALF-LIFE: 26–38 minutes
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Cytochrome P450-metabolized drugs
PREGNANCY CATEGORY: X
Tesamorelin should not be used in children with open epiphyses, among whom excess GH and IGF-I may result in linear growth acceleration and excessive growth.
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OTHER.
Page last updated 01/31/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric